Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06343298 · ClinicalTrials.gov registry record · Phase 2
To Evaluate the Safety and Efficacy of MANP in Subjects With Difficult to Control/ Resistant Hypertension
A Phase 2 study of Difficult to Control Hypertension, sponsored by E-Star BioTech.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 120
- Enrollment target
- 20
- Study locations
NCT06343298: Recruiting Phase 2 study of Difficult to Control Hypertension, sponsored by E-Star BioTech.
NCT06343298 is a Phase 2 study of Difficult to Control Hypertension that is actively recruiting participants, run by E-Star BioTech. The registered enrollment target is 120 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (10% lower). The trial reports 20 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06343298, a Phase 2 study of Difficult to Control Hypertension, is actively recruiting participants, sponsored by E-Star BioTech.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 120 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a Phase 2 dose-titration study designed to evaluate the safety and efficacy of MANP subcutaneous injection compared to placebo in reducing baseline daytime systolic blood pressure (SBP), derived from 24-hour ambulatory blood pressure monitoring (ABPM), in subjects with hypertension who are taking 3 or more antihypertensive medications with different mechanisms of action.
Primary Outcome
ABPM
Conditions Studied
Interventions
- DRUG MANP
- OTHER Placebo Matched control
Study Locations (20)
California
- Amicis Research Center - Beverly Hills - Beverly Hills
- Amicis Research Center - Granada Hills - Granada Hills
- Orange County Research Center - Lake Forest
- Amicis Research Center - Palmdale - Palmdale
- Amicis Research Site - Valencia - Valencia
- Interventional Cardiology Medical Group - West Hills
- Office of Dr. Edward Portnoy MD - Westlake Village
Florida
- SM Research Center - Biscayne Park
- Arrow Clinical Trials - Daytona Beach
- Royal Research Corp - Hollywood
- Evolution Clinical Trials - Miami
Georgia
- Cowry Health - Acworth
- Alta Pharmaceutical Research Center - Peachtree Corners
Michigan
- Revival Research Institute, LLC - Dearborn
- Aa Mrc Llc - Flint
North Carolina
- Monroe Biomedical Research - Monroe
- Superior Clinical Research - Smithfield
Arkansas
- Lynn Institute of the Ozarks - Little Rock
Illinois
- Cedar Crosse Research Center - Chicago
Ohio
- K&R Research LLC - Marion
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2024-11-17 |
| Est. Completion | 2026-09-01 |
| Phase | Phase 2 |
What NCT06343298 shows while recruiting
NCT06343298 is an interventional study that assigns participants to a tested intervention. The registered 120 participants enrollment target is mid-sized for trials with a published cap, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (10% lower).
The record links to 1 condition, with Difficult to Control Hypertension appearing as the primary indexed condition, and to 2 interventions - of which MANP is the first listed.
NCT06343298 names 20 study sites across 8 states, led by California, Florida, Georgia.
Frequently Asked Questions
What is clinical trial NCT06343298 about?
NCT06343298 is a clinical study titled "To Evaluate the Safety and Efficacy of MANP in Subjects With Difficult to Control/ Resistant Hypertension". This is a Phase 2 dose-titration study designed to evaluate the safety and efficacy of MANP subcutaneous injection compared to placebo in reducing baseline daytime systolic blood pressure (SBP), derived from 24-hour ambulatory blood pressure monitoring (ABPM), in subjects with hypertension who are t...
What is the current status of trial NCT06343298?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 120 participants. The study started on 2024-11-17. Estimated completion is 2026-09-01.
What conditions does trial NCT06343298 study?
This clinical trial studies the following conditions: Difficult to Control Hypertension.
What interventions are being tested in trial NCT06343298?
The interventions under investigation include: MANP (DRUG), Placebo Matched control (OTHER).
Who is sponsoring clinical trial NCT06343298?
This trial is sponsored by E-Star BioTech, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06343298 being conducted?
This trial has 20 study locations across Arkansas, California, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06343298's enrollment target sits among peer trials
120 569th of 2000 higher than 1,384 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01174108 · 120 participants · Phase 2
Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells
- NCT01627301 · 120 participants · NA
Sympathetic Overactivity in Post-traumatic Stress Disorder
- NCT02025023 · 120 participants · Phase 3
Local 5-Fluorouracil Injection for the Treatment of Chalazia: A Prospective, Comparative Study
- NCT02128906 · 120 participants · Phase 2
Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI